# Safety and Efficacy Study of Etanercept (Qiangke®) to Treat Moderate to Severe Plaque Psoriasis

> **NCT02701205** · PHASE3 · UNKNOWN · sponsor: **Shanghai Celgen Bio-Pharmaceutical Co.,Ltd** · enrollment: 216 (estimated)

## Conditions studied

- Plaque Psoriasis
- Psoriasis

## Interventions

- **BIOLOGICAL:** etanercept
- **BIOLOGICAL:** etanercept (half dose)
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT02701205
- **Lead sponsor:** Shanghai Celgen Bio-Pharmaceutical Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-01
- **Primary completion:** 2017-01
- **Final completion:** 2017-12
- **Target enrollment:** 216 (ESTIMATED)
- **Last updated:** 2016-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02701205

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02701205, "Safety and Efficacy Study of Etanercept (Qiangke®) to Treat Moderate to Severe Plaque Psoriasis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02701205. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*